- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07691515
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (RAINBOW)
Transcatheter Arterial Chemoembolization in Combination With Tislelizumab Plus Lenvatinib Versus Systemic Cisplatin Plus Gemcitabine in Combination With Tislelizumab for Unresectable Intrahepatic Cholangiocarcinoma: A Phase III, Multicenter, Randomized Controlled Trial
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab as first-line treatment for patients with unresectable intrahepatic cholangiocarcinoma.
Approximately 140 eligible patients with histologically confirmed unresectable intrahepatic cholangiocarcinoma without extrahepatic metastasis will be enrolled and randomized in a 1:1 ratio to receive either TACE plus tislelizumab and lenvatinib or GEMCIS plus tislelizumab. In the TACE-based treatment arm, hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to the protocol.
The primary endpoint is overall survival. Secondary endpoints include progression-free survival, time to progression, objective response rate, disease control rate, safety, and quality of life.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Gaojun Teng, MD
- Número de telefone: +86 13805171500
- E-mail: gjteng@seu.edu.cn
Estude backup de contato
- Nome: Binyan Zhong, MD
- Número de telefone: +86 15850522044
- E-mail: byzhongir@sina.com
Locais de estudo
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- The First Affiliated Hospital, Sun Yat-sen University
-
Contato:
- Ming Kuang
- Número de telefone: 020-87755766
- E-mail: kuangm@mail.sysu.edu.cn
-
Contato:
- Zhenwei Peng
- E-mail: pzhenw@mail.sysu.edu.cn
-
Subinvestigador:
- Wenzhe Fan
-
Guangzhou, Guangdong, China, 510317
- Guangdong Second People's Hospital
-
Contato:
- Chengjiang Xiao
- Número de telefone: +86 13602808387
- E-mail: Xxx196610@163.com
-
Guangzhou, Guangdong, China, 510168
- Jinshazhou Hospital of Guangzhou University of Chinese Medicine
-
Contato:
- Liangliang Qiao
- Número de telefone: +86 13544539881
- E-mail: 271937316@qq.com
-
Guangzhou, Guangdong, China, 511400
- The Affiliated Panyu Central Hospital of Guangzhou Medical University
-
Contato:
- Fuxi Huang
- Número de telefone: +86 18902299938
- E-mail: Fuxihuang2006@126.com
-
Guangzhou, Guangdong, China, 524003
- The Second Affiliated Hospital of Guangdong Medical University
-
Contato:
- Kangshun Zhu
- Número de telefone: +86 13602864242
- E-mail: Zhksh010@163.com
-
Jiangmen, Guangdong, China, 529030
- Jiangmen Central Hospital
-
Contato:
- Yuchuang Liang
- Número de telefone: +86 13322888181
- E-mail: jmlyc@21cn.com
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Wuhan Union Hospital of China
-
Contato:
- Xuefeng Kan
- Número de telefone: +86 13545874189
- E-mail: xkliulang1314@163.com
-
-
Hunan
-
Changsha, Hunan, China, 410013
- The Third XIANGYA Hospital of Central South University
-
Contato:
- Qi Liang
- Número de telefone: +86 137 8731 8180
- E-mail: csuliangqi10@163.com
-
Changsha, Hunan, China, 410011
- The Second Xiangya Hospital of Central South University
-
Contato:
- Yudong Xiao
- Número de telefone: +86 136 3740 3027
- E-mail: xiaoyudong222@csu.edu.cn
-
-
Jiangxi
-
Ganzhou, Jiangxi, China, 341000
- Ganzhou Hospital-Nanfang Hospital, Southern Medical University
-
Contato:
- Yusheng Song
- Número de telefone: +86 135 7675 2988
- E-mail: 646993126@qq.com
-
Nanchang, Jiangxi, China, 330209
- The First Affiliated Hospital of Nanchang University
-
Contato:
- Junhua Ai
- Número de telefone: +86 18170936163
- E-mail: aijh0001@163.com
-
-
Shandong
-
Qingdao, Shandong, China, 266000
- The Affiliated Hospital of Qingdao University
-
Contato:
- Song Wang
- Número de telefone: +86 18661805592
- E-mail: derekqyfy@126.com
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China School of Medicine/West China Hospital, Sichuan University (WCSM/WCH, SCU)
-
Contato:
- Chang Liu
- Número de telefone: +86 18980606382
- E-mail: drliuchang@wchscu.cn
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Zhejiang Cancer Hospital
-
Contato:
- Gaojun Teng
- Número de telefone: +86 0571 - 88122222
- E-mail: gjteng@seu.edu.cn
-
Contato:
- Binyan Zhong
- Número de telefone: +86 15850522044
- E-mail: byzhongir@sina.com
-
Subinvestigador:
- Jiaping Zheng
-
Jinhua, Zhejiang, China, 321000
- Jinhua Municipal Central Hospital
-
Contato:
- Xiaogang Hu
- Número de telefone: +86 135 8866 8173
- E-mail: heartdoctor@163.com
-
Lishui, Zhejiang, China, 323020
- Lishui Central Hospital
-
Contato:
- Jiansong Ji
- Número de telefone: +86 0578-2285888
- E-mail: jjstcty@sina.com
-
Contato:
- Jianfei Tu
- E-mail: jianfei1133@163.com
-
Ningbo, Zhejiang, China, 315010
- Ningbo No.2 Hospital
-
Contato:
- Yunjie Chen
- Número de telefone: +86 13857877137
- E-mail: a88960317@163.com
-
Ningbo, Zhejiang, China, 315048
- Ningbo Medical Center Lihuili Hospital
-
Contato:
- Shengdong Wu
- Número de telefone: +86 13567886669
- E-mail: 13567886669@139.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed intrahepatic cholangiocarcinoma that is unresectable or recurrent after curative treatment, without extrahepatic metastasis.
- No prior systemic therapy or transarterial interventional therapy for intrahepatic cholangiocarcinoma.
- At least one measurable intrahepatic lesion according to RECIST v1.1.
- ECOG performance status of 0 or 1.
- Child-Pugh class A liver function.
- Life expectancy ≥3 months.
Adequate hematologic, hepatic, renal, and thyroid function within 14 days before study start, defined as:
- Absolute neutrophil count ≥1.5 × 10⁹/L;
- Platelet count ≥75 × 10⁹/L;
- Hemoglobin ≥90 g/L;
- Serum albumin ≥30 g/L;
- Total bilirubin ≤1.5 × upper limit of normal;
- AST and ALT <1.5 × upper limit of normal, and ALP <4 × upper limit of normal;
- TSH <1 × upper limit of normal, with T3 and T4 within the normal range;
- Serum creatinine <1.5 × upper limit of normal and creatinine clearance ≥60 mL/min.
Exclusion Criteria:
- Diffuse infiltrative liver lesions.
- Contraindications to TACE.
- Allergy to intravenous contrast agent.
- pregnant or breastfeeding women, or participants planning pregnancy within 2 years / unwilling to use effective contraception.
- Patients with HIV or syphilis infection.
- Patients with concurrent malignancies or other malignancies within 5 years before enrollment.
- History of allogeneic organ transplantation.
- Severe dysfunction of the heart, kidney, or other organs.
- Severe clinically active infection > grade 2 according to NCI-CTC v5.0.
- Psychiatric illness that may affect the informed consent process; Inability to take oral medications; Participation in another drug clinical trial within 12 months before enrollment.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: TACE Plus Tislelizumab and Lenvatinib
Participants will receive tislelizumab 200 mg intravenously every 3 weeks and oral lenvatinib once daily at a starting dose of 12 mg for body weight ≥60 kg or 8 mg for body weight <60 kg.
TACE will be performed after initiation of lenvatinib and may be repeated based on radiologic response, residual viable tumor, liver function, and investigator assessment.
Both conventional TACE (cTACE) and drug-eluting beads TACE are allowed, and hepatic artery infusion chemotherapy may be added at investigator's discretion.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Oral lenvatinib once daily, 12 mg for participants with body weight ≥60 kg or 8 mg for participants with body weight <60 kg, with dose modification according to toxicity.
Conventional TACE or drug-eluting bead TACE are allowed.
TACE may be repeated based on imaging assessment every 6 weeks ±7 days and investigator judgment.
Optional hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to protocol-defined dose ranges.
|
|
Comparador Ativo: Gemcitabine-Cisplatin Plus Tislelizumab
Participants will receive cisplatin 25 mg/m² on Day 1 and Day 8, gemcitabine 1000 mg/m² on Days 1 and 8, and tislelizumab 200 mg on Day 1 of each 3-week cycle for up to 8 cycles.
After completion of gemcitabine-cisplatin treatment, participants will continue tislelizumab 200 mg intravenously every 3 weeks.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Gemcitabine 1000 mg/m² intravenously on Days 1 and 8 of each 21-day cycle, up to 8 cycles.
Cisplatin 25 mg/m² intravenously on Day 1 and Day 8 of each 21-day cycle, up to 8 cycles.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall Survival
Prazo: From randomization to death from any cause, assessed up to approximately 48 months
|
Overall survival is defined as the time from enrollment/randomization to death from any cause.
Participants who withdraw are lost to follow-up or remain alive at the end of the study will be censored at the date they were last known to be alive.
|
From randomization to death from any cause, assessed up to approximately 48 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-Free Survival
Prazo: From randomization to disease progression or death, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression or death from any cause.
Participants without progression or death will be censored at the last date known to be progression-free.
|
From randomization to disease progression or death, assessed up to approximately 48 months
|
|
Time to Progression
Prazo: From randomization to disease progression, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression.
Participants who die without prior progression, withdraw, are lost to follow-up, or remain progression-free at study end will be censored at the last date known to be progression-free.
|
From randomization to disease progression, assessed up to approximately 48 months
|
|
Objective Response Rate
Prazo: Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response or partial response according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Disease Control Rate
Prazo: Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response, partial response, or stable disease according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Incidence of Grade ≥3 Adverse Events
Prazo: From first dose of study treatment through 28 days after the last dose of study treatment
|
Defined as the occurrence of grade 3 or higher hematologic or non-hematologic toxicities, graded according to CTCAE v5.0.
|
From first dose of study treatment through 28 days after the last dose of study treatment
|
|
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Prazo: Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 is a 30-item questionnaire used to assess health-related quality of life in patients with cancer.
Scores are linearly transformed to a 0 to 100 scale.
For the global health status/quality-of-life scale and functional scales, higher scores indicate better health-related quality of life or functioning.
For symptom scales and single symptom items, higher scores indicate a higher symptom burden or worse symptoms.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
|
Quality of Life Assessed by the EuroQol Five-Dimension (EQ-5D)
Prazo: Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The EuroQol Five-Dimension Three-Level Questionnaire is a standardized instrument for measuring health-related quality of life.
The descriptive system includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension is scored from 1 to 3, where 1 indicates no problems, 2 indicates some or moderate problems, and 3 indicates extreme problems or inability to perform the activity.
Higher scores in each dimension indicate more severe problems or worse health status.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Gaojun Teng, MD, Zhejiang Cancer Hospital
- Investigador principal: Min Kuang, MD, First Affiliated Hospital, Sun Yat-Sen University
- Investigador principal: Jiansong Ji, MD, The Central Hospital of Lishui City
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias
- Neoplasias por Tipo Histológico
- Neoplasias Glandulares e Epiteliais
- Adenocarcinoma
- Carcinoma
- Colangiocarcinoma
- Cirrose, familiar, com hipertensão pulmonar
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Produtos químicos inorgânicos
- Compostos de cloro
- Compostos de nitrogênio
- Desoxicitidina
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Compostos de platina
- Gemcitabina
- Cisplatina
- Lenvatinib
- tislelizumab
Outros números de identificação do estudo
- RAINBOW 01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .